NEURAXPHARM AUSTRALIA PTY

Company snapshot

Neurizon Therapeutics Limited (ASX: NUZ), formerly known as PharmAust, is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon strategy is to accelerate access to effective ALS treatments for patients

• 1 approved product(s) across US/EU regulatory metadata.
• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for NEURAXPHARM AUSTRALIA PTY. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for NEURAXPHARM AUSTRALIA PTY.

1. Jun 8, 2026 Clinical update

   NXPTEGO/23/P1-4 — Phase 1

2. Jun 8, 2026 Clinical update

   GFC-BEMD-01-NXP/23 — Phase 1

3. Jun 8, 2026 Clinical update

   NXPLEVE/24/P3-6 — Phase 3

View all clinical trial activity →

• What is NEURAXPHARM AUSTRALIA PTY?

  Neurizon Therapeutics is a pharma organization headquartered in Melbourne, AU. Primary therapeutic focus areas include Refractory Partial Onset Epilepsy, Multiple Sclerosis. NovaPharmaNews links 3 clinical program(s), 1 drug profile(s), and 0 patent record(s) to this entity from

• Is NEURAXPHARM AUSTRALIA PTY publicly traded?

  NEURAXPHARM AUSTRALIA PTY appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does NEURAXPHARM AUSTRALIA PTY develop or market?

  We link 17 drug profile(s) where NEURAXPHARM AUSTRALIA PTY is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/neuraxpharm-pharmaceuticals-s-l#company-drugs.

• What are the latest developments for NEURAXPHARM AUSTRALIA PTY?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does NEURAXPHARM AUSTRALIA PTY focus on?

  NEURAXPHARM AUSTRALIA PTY focuses on Refractory Partial Onset Epilepsy, Multiple Sclerosis based on our analysis of their pipeline programs and drug development activities.